Cellid, Co., Ltd. (299660.KQ)

KRW 5500.0

(-7.25%)

Total Liabilities Summary of Cellid, Co., Ltd.

Cellid, Co., Ltd.'s latest annual total liabilities in 2023 was 23.42 Billion KRW , up 0.04% from previous year.
Cellid, Co., Ltd.'s latest quarterly total liabilities in 2024 Q2 was 18.94 Billion KRW , down -24.82% from previous quarter.
Cellid, Co., Ltd. reported annual total liabilities of 23.41 Billion KRW in 2022, up 20.12% from previous year.
Cellid, Co., Ltd. reported annual total liabilities of 19.49 Billion KRW in 2021, up 826.53% from previous year.
Cellid, Co., Ltd. reported quarterly total liabilities of 18.94 Billion KRW for 2024 Q2, down -24.82% from previous quarter.
Cellid, Co., Ltd. reported quarterly total liabilities of 15.62 Billion KRW for 2023 Q2, down -1.94% from previous quarter.

Annual Total Liabilities Chart of Cellid, Co., Ltd. (2023 - 2015)

Historical Annual Total Liabilities of Cellid, Co., Ltd. (2023 - 2015)

Year	Total Liabilities	Total Liabilities Growth
2023	23.42 Billion KRW	0.04%
2022	23.41 Billion KRW	20.12%
2021	19.49 Billion KRW	826.53%
2020	2.1 Billion KRW	77.41%
2019	1.18 Billion KRW	64.58%
2018	720.62 Million KRW	-93.13%
2017	10.49 Billion KRW	161.36%
2016	4.01 Billion KRW	114.39%
2015	1.87 Billion KRW	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	25.19 Billion KRW	7.55%
2024 Q2	18.94 Billion KRW	-24.82%
2023 Q2	15.62 Billion KRW	-1.94%
2023 Q1	15.92 Billion KRW	-31.98%
2023 Q4	23.42 Billion KRW	10.12%
2023 Q3	21.27 Billion KRW	36.18%
2023 FY	23.42 Billion KRW	0.04%
2022 Q4	23.41 Billion KRW	13.48%
2022 Q2	19.6 Billion KRW	3.34%
2022 FY	23.41 Billion KRW	20.12%
2022 Q1	18.96 Billion KRW	-2.71%
2022 Q3	20.63 Billion KRW	5.29%
2021 Q2	15.04 Billion KRW	3.44%
2021 FY	19.49 Billion KRW	826.53%
2021 Q3	14.68 Billion KRW	-2.38%
2021 Q4	19.49 Billion KRW	32.75%
2021 Q1	14.54 Billion KRW	591.17%
2020 Q1	1.44 Billion KRW	21.66%
2020 Q2	1.32 Billion KRW	-8.43%
2020 FY	2.1 Billion KRW	77.41%
2020 Q3	1.32 Billion KRW	0.13%
2020 Q4	2.1 Billion KRW	59.04%
2019 FY	1.18 Billion KRW	64.58%
2019 Q3	2.88 Billion KRW	74.79%
2019 Q1	1.4 Billion KRW	269.67%
2019 Q4	1.18 Billion KRW	-58.87%
2019 Q2	1.64 Billion KRW	17.8%
2018 Q1	- KRW	-100.0%
2018 FY	720.62 Million KRW	-93.13%
2018 Q2	1.21 Billion KRW	0.0%
2018 Q4	378.87 Million KRW	0.0%
2017 FY	10.49 Billion KRW	161.36%
2017 Q1	- KRW	0.0%
2017 Q4	4.15 Billion KRW	0.0%
2016 FY	4.01 Billion KRW	114.39%
2015 FY	1.87 Billion KRW	0.0%

Peer Total Liabilities Comparison of Cellid, Co., Ltd.

Name	Total Liabilities	Total Liabilities Difference
Sam Chun Dang Pharm. Co., Ltd	109.56 Billion KRW	78.618%
Hyundai Bioscience Co., Ltd.	7.52 Billion KRW	-211.498%
ST Pharm Co.,Ltd.	299.92 Billion KRW	92.189%
ABL Bio Inc.	86.06 Billion KRW	72.78%